About Company

Mehdi Chelbi

Mehdi is an entrepreneur in Biotech and Healthcare with nearly 20 years of experience in Drug Discovery, Preclinical Development, Clinical Development, Regulatory Affairs and Post-Marketed Studies.

Mehdi co-founded several start up Biotech and Life Sciences companies for which he has C-Level and/or Board member positions. Mehdi is also Board member and Advisor for innovative life science and pharma companies. Prior to founding BiPER Therapeutics, Mehdi was Director and Member of Executive Committee of an international clinical research organization, where he successfully managed its global expansion, including the development of the European headquarters and the opening of 2 offices in North America. Mehdi holds a MSc in Biology and started his career in business development by joining a company specialized in therapeutic drug discovery and preclinical development.

Mickel Cerezo

Obtained master degree in genetics, development and immunity from the University of Nice Sophia-Antipolis in France in 2010, Michale have earned his PhD in the laboratory of Dr. Robert Ballotti (C3M, Nice) in 2014 where he identified new active BiP inhibitors a new family of compound interfering with protein folding pathway to target melanoma cell proliferation and resistance to therapy. In 2015, he joined the laboratory of the Pr. Caroline Robert in Gustave Roussy Institute to understand how mRNA translation pathway and particularly translation initiation complex eIF4F affect response to immunotherapy. In 2020, he joined Rocchi/Passeron team to study metabolic alterations driving melanoma immunotherapy resistance and BiPER Therapeutics acting Chief Operating Officer

Stephane Milot

Stéphane Milot holds a master’s degree in finance and accounting from the University Paris Dauphine, and his degree is equivalent to a CPA. After an experience as a consultant with PwC and Anderson, Stéphane moved into the healthcare industry 15 years ago; his experience includes Finance Director at KaVo Dental and co-founder and finance director at Implanet and Beep N Track. Since 2011, Stéphane has been supporting innovative enterprises in the healthcare sector in their financing strategy. Specializing in raising funds, Stéphane has participated in several financing rounds raising more than 40 million euros. In addition, he assists in the organization, supervision and administration of companies as well as the deployment of information systems. He was notably a Finance Director at Pathoquest before joining BiPER Therapeutics. At BiPER Therapeutics, Stéphane is in charge of corporate financing and accounting management

Alain Thibaut

Alkain Thibault obtained his Medical Degree at McGill University Montreal, Canada and Board Certification in Oncology and Internal Medicine in the US. He has held management and specialist positions at Roche, J&J and Regeneron as well as Chief Medical Officer roles in biotech companies. Alain has as a medical oncologist extensive global experience leading novel compounds through clinical development.

Guillaume Vetter-Genoud

Director of Quest For Health, a healthcare startup accelerator for the French Grand Est region, member of Quest for change incubators networks. The accelerator currently supports more than 70 start-ups in the biotech, medtech and e-health sectors and is the French leader for start-ups in these sectors. Guillaume holds a PhD in molecular & cellular biology at University of Strasbourg, and a MBA from Montpellier Business School. Before joining Quest for Health, he was successively researcher, assistant-professor and Director of a biotech startup that was acquired by Theradiag as part of its IPO. Laureate of the World Innovation Contest (2014), he is also currently mentor and board member of 4 medtech and biotech startups.

Mehdi Chelbi

Mehdi is an entrepreneur in Biotech and Healthcare with nearly 20 years of experience in Drug Discovery, Preclinical Development, Clinical Development, Regulatory Affairs and Post-Marketed Studies.

Mehdi co-founded several start up Biotech and Life Sciences companies for which he has C-Level and/or Board member positions. Mehdi is also Board member and Advisor for innovative life science and pharma companies. Prior to founding BiPER Therapeutics, Mehdi was Director and Member of Executive Committee of an international clinical research organization, where he successfully managed its global expansion, including the development of the European headquarters and the opening of 2 offices in North America. Mehdi holds a MSc in Biology and started his career in business development by joining a company specialized in therapeutic drug discovery and preclinical development.

Mehdi Chelbi

Mehdi is an entrepreneur in Biotech and Healthcare with nearly 20 years of experience in Drug Discovery, Preclinical Development, Clinical Development, Regulatory Affairs and Post-Marketed Studies.

Mehdi co-founded several start up Biotech and Life Sciences companies for which he has C-Level and/or Board member positions. Mehdi is also Board member and Advisor for innovative life science and pharma companies. Prior to founding BiPER Therapeutics, Mehdi was Director and Member of Executive Committee of an international clinical research organization, where he successfully managed its global expansion, including the development of the European headquarters and the opening of 2 offices in North America. Mehdi holds a MSc in Biology and started his career in business development by joining a company specialized in therapeutic drug discovery and preclinical development.

Mehdi Chelbi

Mehdi is an entrepreneur in Biotech and Healthcare with nearly 20 years of experience in Drug Discovery, Preclinical Development, Clinical Development, Regulatory Affairs and Post-Marketed Studies.

Mehdi co-founded several start up Biotech and Life Sciences companies for which he has C-Level and/or Board member positions. Mehdi is also Board member and Advisor for innovative life science and pharma companies. Prior to founding BiPER Therapeutics, Mehdi was Director and Member of Executive Committee of an international clinical research organization, where he successfully managed its global expansion, including the development of the European headquarters and the opening of 2 offices in North America. Mehdi holds a MSc in Biology and started his career in business development by joining a company specialized in therapeutic drug discovery and preclinical development.

Stephane Rocchi

Stéphane Rocchi is INSERM research director at the Mediterranean Center for Molecular Medicine where he has been working for many years on a very aggressive skin cancer, melanoma. S Rocchi's team is developing translational projects with the dermatology department of the Nice University Hospital. In addition, as of January 1, 2018, S Rocchi and T Passeron, PU / PH in the Department of Dermatology, are co-developing a new research team at C3M entitled "Study of molecular mechanisms involved in pigmentation and melanoma by translational approaches".

Pr Sylvie Rottey

For the last twenty years, prof. dr. Rottey is involved in international high-level research towards novel therapeutic options for patients with various solid tumors. In this matter, immunotherapy is becoming the state of the art for therapy of several solid tumors. As prof. dr. Rottey is leading phase I oncology clinical trials for the last decade, she has worked and continues to work with different immunotherapies in development. Next, prof. dr. Rottey is continuously involved in high-quality state of the art research for both novel therapeutic options for patients with solid tumors (both genitourinary; namely urothelial carcinoma, renal cell carcinoma and prostate cancer; and head and neck tumors) as well as new diagnostic biomarkers that could have predictive and prognostic value in these patient populations

Pr Romain Coriat

Mehdi is an entrepreneur in Biotech and Healthcare with nearly 20 years of experience in Drug Discovery, Preclinical Development, Clinical Development, Regulatory Affairs and Post-Marketed Studies.

Mehdi co-founded several start up Biotech and Life Sciences companies for which he has C-Level and/or Board member positions. Mehdi is also Board member and Advisor for innovative life science and pharma companies. Prior to founding BiPER Therapeutics, Mehdi was Director and Member of Executive Committee of an international clinical research organization, where he successfully managed its global expansion, including the development of the European headquarters and the opening of 2 offices in North America. Mehdi holds a MSc in Biology and started his career in business development by joining a company specialized in therapeutic drug discovery and preclinical development.

Pr Amy S Lee

Obtained PhD from the California Institute of Technology. Currently Professor of Biochemistry and Molecular Biology at the University of Southern California, Keck School of Medicine. Expert in the mammalian stress response, GRP78 and cancer biology.

Dr Neil Sankhar

Dr. Sankar received his training in clinical research and tumor biology from NCI Bethesda, Maryland and since has held clinical development positions within leading Biotech/Pharma including Genentech, Medimmune, Pharmacyclis, Fiveprime, Otsuka, Portola, CBT Pharmaceuticals, LSK biopharma and Rhizen Pharmaceuticals. As an expert in providing global clinical development and regulatory strategies for therapeutic drugs, Dr. Sankar has acted as the clinical lead in numerous phase I, II and III clinical trials. He is and was instrumental in filing the New Drug Applications for the antibody-drug conjugate Kadcyla and the B cell receptor signaling kinase inhibitor Ibrutinib.

He has extensive experience in the application of U.S. Food and Drug Administration regulations and the Good Clinical Practice guidelines set forth by the International Council on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Dr. Sankar is an active member of the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the European Hematology Association (EHA , Drug information association (DIA) , European society of clinical oncology (ESMO), American Association for Cancer Research (AACR), Enterprising Pharmaceutical Professionals from the Indian Sub-Continent (EPPIC GLOBAL), Connective Tissue Oncology Society (CTOS), and TiE Silicon Valley.

Neil Sankar received his M.D. degree from Bangalore University and internal medicine residency from University of West Indies, Kingston, Jamaica and trained in the UK and the Caribbean’s. He also holds a postgraduate degree in Public Health from Queensland University in Australia. Neil received his oncology training at the National Cancer Institute at the NIH in Bethesda, MD.

Dr Neil Sankhar

Dr. Sankar received his training in clinical research and tumor biology from NCI Bethesda, Maryland and since has held clinical development positions within leading Biotech/Pharma including Genentech, Medimmune, Pharmacyclis, Fiveprime, Otsuka, Portola, CBT Pharmaceuticals, LSK biopharma and Rhizen Pharmaceuticals. As an expert in providing global clinical development and regulatory strategies for therapeutic drugs, Dr. Sankar has acted as the clinical lead in numerous phase I, II and III clinical trials. He is and was instrumental in filing the New Drug Applications for the antibody-drug conjugate Kadcyla and the B cell receptor signaling kinase inhibitor Ibrutinib.

He has extensive experience in the application of U.S. Food and Drug Administration regulations and the Good Clinical Practice guidelines set forth by the International Council on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Dr. Sankar is an active member of the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the European Hematology Association (EHA , Drug information association (DIA) , European society of clinical oncology (ESMO), American Association for Cancer Research (AACR), Enterprising Pharmaceutical Professionals from the Indian Sub-Continent (EPPIC GLOBAL), Connective Tissue Oncology Society (CTOS), and TiE Silicon Valley.

Neil Sankar received his M.D. degree from Bangalore University and internal medicine residency from University of West Indies, Kingston, Jamaica and trained in the UK and the Caribbean’s. He also holds a postgraduate degree in Public Health from Queensland University in Australia. Neil received his oncology training at the National Cancer Institute at the NIH in Bethesda, MD.

Thierry Passeron

Mehdi is an entrepreneur in Biotech and Healthcare with nearly 20 years of experience in Drug Discovery, Preclinical Development, Clinical Development, Regulatory Affairs and Post-Marketed Studies.

Mehdi co-founded several start up Biotech and Life Sciences companies for which he has C-Level and/or Board member positions. Mehdi is also Board member and Advisor for innovative life science and pharma companies. Prior to founding BiPER Therapeutics, Mehdi was Director and Member of Executive Committee of an international clinical research organization, where he successfully managed its global expansion, including the development of the European headquarters and the opening of 2 offices in North America. Mehdi holds a MSc in Biology and started his career in business development by joining a company specialized in therapeutic drug discovery and preclinical development.